Aytu Biopharma, Inc (AYTU) — 10-K Filings
All 10-K filings from Aytu Biopharma, Inc. Browse 2 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (2)
-
AYTU Bets on Antidepressant EXXUA Amidst $13.6M Loss
— Sep 23, 2025 Risk: high
AYTU BIOPHARMA, INC. reported a net loss of $13.6 million for the fiscal year ended June 30, 2025, contributing to an accumulated deficit of $333.5 million. Des -
Aytu BioPharma Files 2024 10-K: $50M Assets, $5.5M Liabilities
— Sep 26, 2024 Risk: medium
Aytu BioPharma, Inc. filed its 10-K for the fiscal year ending June 30, 2024, reporting total assets of $50 million and total liabilities of $5.5 million. The c
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX